Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2006

Open Access 01-12-2006 | Research article

Joint distribution approaches to simultaneously quantifying benefit and risk

Authors: Michele L Shaffer, Kristi L Watterberg

Published in: BMC Medical Research Methodology | Issue 1/2006

Login to get access

Abstract

Background

The benefit-risk ratio has been proposed to measure the tradeoff between benefits and risks of two therapies for a single binary measure of efficacy and a single adverse event. The ratio is calculated from the difference in risk and difference in benefit between therapies. Small sample sizes or expected differences in benefit or risk can lead to no solution or problematic solutions for confidence intervals.

Methods

Alternatively, using the joint distribution of benefit and risk, confidence regions for the differences in risk and benefit can be constructed in the benefit-risk plane. The information in the joint distribution can be summarized by choosing regions of interest in this plane. Using Bayesian methodology provides a very flexible framework for summarizing information in the joint distribution.

Results

Data from a National Institute of Child Health & Human Development trial of hydrocortisone illustrate the construction of confidence regions and regions of interest in the benefit-risk plane, where benefit is survival without supplemental oxygen at 36 weeks postmenstrual age, and risk is gastrointestinal perforation. For the subgroup of infants exposed to chorioamnionitis the confidence interval based on the benefit-risk ratio is wide (Benefit-risk ratio: 1.52; 90% confidence interval: 0.23 to 5.25). Choosing regions of appreciable risk and acceptable risk in the benefit-risk plane confirms the uncertainty seen in the wide confidence interval for the benefit-risk ratio – there is a greater than 50% chance of falling into the region of acceptable risk – while visually allowing the uncertainty in risk and benefit to be shown separately. Applying Bayesian methodology, an incremental net health benefit analysis shows there is a 72% chance of having a positive incremental net benefit if hydrocortisone is used in place of placebo if one is willing to incur at most one gastrointestinal perforation for each additional infant that survives without supplemental oxygen.

Conclusion

If the benefit-risk ratio is presented, the joint distribution of benefit and risk also should be shown. These regions avoid the ambiguity associated with collapsing benefit and risk to a single dimension. Bayesian methods allow even greater flexibility in simultaneously quantifying benefit and risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference Willan AR, O'Brien BJ, Cook DJ: Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. Control Clin Trials. 1997, 18: 121-130. 10.1016/S0197-2456(96)00092-X.CrossRefPubMed Willan AR, O'Brien BJ, Cook DJ: Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. Control Clin Trials. 1997, 18: 121-130. 10.1016/S0197-2456(96)00092-X.CrossRefPubMed
2.
go back to reference Heitjan DF, Moskowitz AJ, Whang W: Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ. 1999, 8: 191-201. 10.1002/(SICI)1099-1050(199905)8:3<191::AID-HEC409>3.0.CO;2-R.CrossRefPubMed Heitjan DF, Moskowitz AJ, Whang W: Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ. 1999, 8: 191-201. 10.1002/(SICI)1099-1050(199905)8:3<191::AID-HEC409>3.0.CO;2-R.CrossRefPubMed
3.
go back to reference Willan AR, O'Brien BJ: Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Econ. 1996, 5: 297-305. 10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T.CrossRefPubMed Willan AR, O'Brien BJ: Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Econ. 1996, 5: 297-305. 10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T.CrossRefPubMed
4.
go back to reference Heitjan DF, Moskowitz AJ, Whang W: Problems with interval estimates of the incremental cost-effectiveness ratio. Med Decis Making. 1999, 19: 9-15.CrossRefPubMed Heitjan DF, Moskowitz AJ, Whang W: Problems with interval estimates of the incremental cost-effectiveness ratio. Med Decis Making. 1999, 19: 9-15.CrossRefPubMed
7.
go back to reference Efron B: The jackknife, the bootstrap and other resampling plans. 1982, SIAM [Society for Industrial and Applied Mathematics]CrossRef Efron B: The jackknife, the bootstrap and other resampling plans. 1982, SIAM [Society for Industrial and Applied Mathematics]CrossRef
8.
go back to reference Briggs AH, Wonderling DE, Mooney CZ: Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997, 6: 327-340. 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W.CrossRefPubMed Briggs AH, Wonderling DE, Mooney CZ: Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997, 6: 327-340. 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W.CrossRefPubMed
9.
go back to reference Heitjan DF, Kim CY, Li H: Bayesian estimation of cost-effectiveness from censored data. Stat Med. 2004, 23: 1297-1309. 10.1002/sim.1740.CrossRefPubMed Heitjan DF, Kim CY, Li H: Bayesian estimation of cost-effectiveness from censored data. Stat Med. 2004, 23: 1297-1309. 10.1002/sim.1740.CrossRefPubMed
10.
go back to reference Tallarida RJ, Murray RB, Eiben C: A scale for assessing the severity of diseases and adverse drug reactions. Clin Pharmacol Ther. 1979, 25: 381-390.CrossRefPubMed Tallarida RJ, Murray RB, Eiben C: A scale for assessing the severity of diseases and adverse drug reactions. Clin Pharmacol Ther. 1979, 25: 381-390.CrossRefPubMed
11.
go back to reference Chuang-Stein C, Mohberg NR, Sinkula MS: Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat Med. 1991, 10: 1349-1359.CrossRefPubMed Chuang-Stein C, Mohberg NR, Sinkula MS: Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat Med. 1991, 10: 1349-1359.CrossRefPubMed
12.
go back to reference Chuang-Stein C, Mohberg NR, Musselman DM: Organization and analysis of safety data using a multivariate approach. Stat Med. 1992, 11: 1075-1089.CrossRefPubMed Chuang-Stein C, Mohberg NR, Musselman DM: Organization and analysis of safety data using a multivariate approach. Stat Med. 1992, 11: 1075-1089.CrossRefPubMed
13.
go back to reference Chuang-Stein C: A new proposal for benefit-less-risk analysis in clinical trials. Control Clin Trials. 1994, 15: 30-43. 10.1016/0197-2456(94)90026-4.CrossRefPubMed Chuang-Stein C: A new proposal for benefit-less-risk analysis in clinical trials. Control Clin Trials. 1994, 15: 30-43. 10.1016/0197-2456(94)90026-4.CrossRefPubMed
14.
go back to reference Holden WL: Benefit-risk analysis: a brief review and proposed quantitative approaches. Drug Saf. 2003, 26: 853-862. 10.2165/00002018-200326120-00002.CrossRefPubMed Holden WL: Benefit-risk analysis: a brief review and proposed quantitative approaches. Drug Saf. 2003, 26: 853-862. 10.2165/00002018-200326120-00002.CrossRefPubMed
15.
go back to reference van Hout BA, Al MJ, Gordon GS, Rutten FF: Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994, 3: 309-319.CrossRefPubMed van Hout BA, Al MJ, Gordon GS, Rutten FF: Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994, 3: 309-319.CrossRefPubMed
17.
go back to reference Hall P: On the bootstrap and likelihood-based confidence regions. Biometrika. 1987, 74: 481-493. 10.2307/2336687.CrossRef Hall P: On the bootstrap and likelihood-based confidence regions. Biometrika. 1987, 74: 481-493. 10.2307/2336687.CrossRef
18.
go back to reference Gelman A, Carlin JB, Stern HS, Rubin DB: Bayesian Data Analysis. 1995, London: Chapman & Hall Gelman A, Carlin JB, Stern HS, Rubin DB: Bayesian Data Analysis. 1995, London: Chapman & Hall
19.
go back to reference Berger JO: Statistical Decision Theory and Bayesian Analysis. 1985, New York: Springer, SecondCrossRef Berger JO: Statistical Decision Theory and Bayesian Analysis. 1985, New York: Springer, SecondCrossRef
20.
go back to reference Stinnett AA, Mullahy J: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998, 18: S68-S80.CrossRefPubMed Stinnett AA, Mullahy J: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998, 18: S68-S80.CrossRefPubMed
21.
go back to reference Willan AR: Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data. Control Clin Trials. 2001, 22: 228-237. 10.1016/S0197-2456(01)00110-6.CrossRefPubMed Willan AR: Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data. Control Clin Trials. 2001, 22: 228-237. 10.1016/S0197-2456(01)00110-6.CrossRefPubMed
22.
go back to reference Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, Couser RJ, Garland JS, Rozycki HJ, Leach CL, Backstrom C, Shaffer ML: Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004, 114: 1649-1657. 10.1542/peds.2004-1159.CrossRefPubMed Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, Couser RJ, Garland JS, Rozycki HJ, Leach CL, Backstrom C, Shaffer ML: Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004, 114: 1649-1657. 10.1542/peds.2004-1159.CrossRefPubMed
23.
go back to reference Watterberg KL, Gerdes JS, Gifford KL, Lin HM: Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999, 104: 1258-1263. 10.1542/peds.104.6.1258.CrossRefPubMed Watterberg KL, Gerdes JS, Gifford KL, Lin HM: Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999, 104: 1258-1263. 10.1542/peds.104.6.1258.CrossRefPubMed
Metadata
Title
Joint distribution approaches to simultaneously quantifying benefit and risk
Authors
Michele L Shaffer
Kristi L Watterberg
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2006
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/1471-2288-6-48

Other articles of this Issue 1/2006

BMC Medical Research Methodology 1/2006 Go to the issue